# Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers

> **NCT04270864** · PHASE1 · TERMINATED · sponsor: **Gustave Roussy, Cancer Campus, Grand Paris** · enrollment: 25 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Tilsotolimod

## Key facts

- **NCT ID:** NCT04270864
- **Lead sponsor:** Gustave Roussy, Cancer Campus, Grand Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-04-10
- **Primary completion:** 2021-07-13
- **Final completion:** 2023-09-25
- **Target enrollment:** 25 (ACTUAL)
- **Why stopped:** The part A of the trial has been completed according to the protocol. The part B has not been opened because of unfeasibility (experimental products not yet available).
- **Last updated:** 2024-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04270864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04270864, "Intratumoral Tilsotolimod, a TLR-9 Agonist, Together With Intratumoral Ipilimumab and Intravenous Nivolumab in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04270864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*